Company profile: Ventyx Biosciences
1.1 - Company Overview
Company description
- Provider of oral therapies for autoimmune, inflammatory and neurodegenerative disorders: VTX3232, a CNS-penetrant NLRP3 inhibitor for Parkinsonβs, obesity, Alzheimerβs and multiple sclerosis; VTX2735, an NLRP3 inhibitor for systemic inflammation, initially cardiovascular; VTX002, an S1P1R modulator for ulcerative colitis; and VTX958, a TYK2 inhibitor for Crohnβs disease.
Products and services
- VTX002: An oral S1P1R modulator in development for ulcerative colitis, engineered to target sphingosine 1 phosphate receptor 1 for colitis-specific therapy
- VTX2735: A selective NLRP3 inhibitor developed for systemic inflammatory conditions, built to target NLRP3 with initial focus on cardiovascular diseases
- VTX3232: A CNS-penetrant NLRP3 inhibitor aimed at neuroinflammatory and neurodegenerative conditions including Parkinsonβs disease, obesity, Alzheimerβs disease, and multiple sclerosis, constructed for central nervous system engagement
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Ventyx Biosciences
Pandion Therapeutics
HQ: United States
Website
- Description: Provider of bispecific antibody therapeutics, modular proteins, and antibodies for localized immunomodulation at the site of disease, enabling durable, tissue-specific treatment for patients with autoimmune and inflammatory diseases and organ transplants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Pandion Therapeutics company profile β
Zura Bio
HQ: United States
Website
- Description: Provider of therapies for immune system disorders, advancing Phase 2 clinical programs including torudokimab (monoclonal antibody targeting IL33), ZB-168 (anti-IL7RΞ± monoclonal antibody inhibiting IL7/TSLP pathways with potential across T-cellβmediated diseases), and ZB-106 (tibulizumab), a bispecific antagonist of IL-17A and BAFF.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Zura Bio company profile β
Hansa Biopharma
HQ: Sweden
Website
- Description: Provider of immunomodulatory treatments for rare immunological diseases, including Imlifidase, a first-generation IgG-cleaving enzyme for rapid inactivation of IgG antibodies via single intravenous treatment. Offers a proprietary enzyme technology platform targeting pathogenic antibodies across transplantation, autoimmunity, gene therapy and oncology, supported by strategic partnerships and sustainability initiatives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Hansa Biopharma company profile β
Graviton
HQ: United States
Website
- Description: Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Graviton company profile β
Pliant Therapeutics
HQ: United States
Website
- Description: Provider of integrin-targeted therapies, including bexotegrast (PLN-74809) for IPF and PSC (oral dual Ξ±vΞ²6/Ξ±vΞ²1 inhibitor), PLN-1474 for MASH (Ξ±vΞ²1 inhibitor for late-stage liver fibrosis), PLN-101095 for oncology (targets Ξ±vΞ²8-mediated TGF-Ξ² activation to increase sensitivity to checkpoint inhibition therapies), and PLN-101325 for muscular dystrophy (Ξ±7Ξ²1 integrin activating antibody).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Pliant Therapeutics company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Ventyx Biosciences
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ventyx Biosciences
2.2 - Growth funds investing in similar companies to Ventyx Biosciences
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Ventyx Biosciences
4.2 - Public trading comparable groups for Ventyx Biosciences
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β